Antiparasitic agent-9 (compound 47) is a highly active and orally administered antiparasitic agent, exhibiting potent antiparasitic efficacy against the human parasite [1].

Antiparasitic agent-9 (compound 47) (15 mg/kg, Orally, twice each day for 7 days) reduces adult worm burden in the jird L. sigmodontis infection model [1]. Antiparasitic agent-9 (2 mg/kg (IV), 10 and 30 mg/kg (PO); once) shows a brain to plasma ratio of 0.08, suggesting limited brain exposure [1]. Animal Model: Female BALB/c mice (infected with L. sigmodontis, 6-8 weeks) [1] Dosage: 15 mg/kg Administration: Orally, twice each day for 7 days Result: Showed a significant worm burden reduction of 59% at 15 mg/kg. Animal Model: Male CD-1 mouse (n = 4) [1] Dosage: 2 mg/kg (IV), 10 and 30 mg/kg (PO) Administration: IV, PO, once (Pharmacokinetic Analysis) Result: Pharmacokinetic Parameters of Antiparasitic agent-9 in male Male CD-1 mouse [1]. PO (30 mg/kg) PO (10 mg/kg) IV (2 mg/kg) C max (μM) 13.9 5.27 ± 0.83 T max (h) 0.50 4.0 ± 2.8 AUC 0-inf (μM·h) 121 68.1±NC CL (mL/min/kg) 3.6 ± 0.22 Vd ss (mL/kg) 0.74 ± 0.08 F (%) 57 brain/plasma [b]/[p] 0.08 efflux ratio (ER) 12